id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-330786-52xyuwum	Jones, C. M.	Considerations for the Treatment of Oesophageal Cancer With Radiotherapy During the COVID-19 Pandemic	2020-04-09		.txt	text/plain	2083	107	42	Consensus was sought for evidence-based approaches to the management of oesophageal cancer that would maintain benefit, minimise risk to the patient, accommodate for service pressures and limit hospital attendance. Standard treatment approaches for potentially curable oesophageal cancer typically comprise neoadjuvant chemotherapy or chemoradiotherapy (CRT) followed by either resection or definitive CRT (dCRT), with some patients receiving postoperative chemotherapy or CRT dependent on resection margins and performance status. If there is uncertainty related to surgical capacity, we would suggest that dCRT with no neoadjuvant or induction component is the most appropriate option to provide an upfront definitive treatment approach while limiting infection risk. In patients for whom the risks of dCRT are considered too great, or in instances where there is limited chemotherapy provision, consider definitive hypofractionated radiotherapy for locally advanced disease. Tumours of up to 5 cm Table 1 A summary of recommendations for the radiotherapy-based management of patients with oesophageal cancer during the coronavirus disease 2019 (COVID-19) pandemic.	./cache/cord-330786-52xyuwum.txt	./txt/cord-330786-52xyuwum.txt